BRAF and melanoma: This was first studied in vitro, where treatment of BRAF-mutant melanoma cell lines was associated with a significant increase in expression of Melanocyte Differentiation Antigens (MDA), including MART-1, gp-100, TYRP-1 and TYRP-2.